Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in immune-mediated inflammatory diseases
Authors' conclusion
These findings demonstrate that IL-2LD not only expands and activates Treg cells but also shapes an anti-inflammatory transcriptomic landscape characterised by ISG downregulation in Treg and Tconv cells. Baseline ISG expression was associated with treatment response, supporting its evaluation as a candidate biomarker for IL-2LD therapy.
Study context
- Population
- Patients with various immune-mediated inflammatory diseases, predominantly autoimmune disorders, treated with IL-2LD
- Participants
- 23 patients
- Outcome
- Transcriptomic effects of IL-2LD in Treg and Tconv
Methodological detailstranscriptomic analysis of the TRANSREG open-label, exploratory basket trial, baseline, day 8 and month 3 samples, gene network analysis and multivariate modelling
- Transcriptomic analysis of the TRANSREG open-label, exploratory basket trial
- Baseline, day 8 and month 3 samples
- Gene network analysis and multivariate modelling
Main finding
As reported in the abstract
- Broad immune transcriptomic changes, predominantly in Treg cells
- Progressive downregulation of interferon-stimulated genes (ISGs) in both Treg and Tconv cells, including GBP1, IFIT2, IFIT3, and RSAD2
- Multivariate model based on baseline ISG expression showed promise for predicting clinical response status
Original publication
Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in immune-mediated inflammatory diseases. Ann Rheum Dis. Published 19 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →